Last reviewed · How we verify
PF-07104091 + PF-07220060 + fulvestrant dose expansion (pf-07104091-pf-07220060-fulvestrant-dose-expansion)
PF-07104091 + PF-07220060 + fulvestrant dose expansion (generic name: pf-07104091-pf-07220060-fulvestrant-dose-expansion) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | pf-07104091-pf-07220060-fulvestrant-dose-expansion |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07104091 + PF-07220060 + fulvestrant dose expansion CI brief — competitive landscape report
- PF-07104091 + PF-07220060 + fulvestrant dose expansion updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-07104091 + PF-07220060 + fulvestrant dose expansion
What is PF-07104091 + PF-07220060 + fulvestrant dose expansion?
PF-07104091 + PF-07220060 + fulvestrant dose expansion (pf-07104091-pf-07220060-fulvestrant-dose-expansion) is a pharmaceutical drug developed by Pfizer Inc..
Who makes PF-07104091 + PF-07220060 + fulvestrant dose expansion?
PF-07104091 + PF-07220060 + fulvestrant dose expansion is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of PF-07104091 + PF-07220060 + fulvestrant dose expansion?
pf-07104091-pf-07220060-fulvestrant-dose-expansion is the generic (nonproprietary) name of PF-07104091 + PF-07220060 + fulvestrant dose expansion.
What development phase is PF-07104091 + PF-07220060 + fulvestrant dose expansion in?
PF-07104091 + PF-07220060 + fulvestrant dose expansion is in Phase 1.